Anifrolumab met primary and secondary endpoints in lupus trial
10 November 2015 | By Victoria White
Anifrolumab is a new monoclonal antibody against the type I interferon (IFN) receptor that inhibits the activity of all type I IFNs, which play a central role in lupus...